Dihydrosomatostatin incorporates a reduced peptide backbone that influences conformational rigidity and stability. Residue diversity supports investigations of binding dynamics, folding behavior, and solvent interactions. Researchers examine its structural transitions to understand hydrogen-bond networks. Use spans peptide analog design, structural modeling, and signaling-pathway exploration.
CAT No: R2646
CAS No:40958-31-4
Synonyms/Alias:Dihydrosomatostatin;Somatostatin-14 (reduced);40958-31-4;Somatostatin (15-28);Somatostatin (sheep reduced);DTXSID00193961;SCHEMBL11592550;SCHEMBL25286356;Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys;DTXCID40116452;HY-P4917;DA-67693;FS109331;CS-0674980;NS00126763;H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH;H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH; H-AGCKNFFWKTFTSC-OH;Somatostatin-14 (reduced) (H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH);
2. Implications of ligand-receptor binding kinetics on GLP-1R signalling
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.